- Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study
- Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024
- Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024
- Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024
- Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154
More ▼
Key statistics
On Wednesday, Lipocine Inc (LPCN:NAQ) closed at 5.95, 157.56% above the 52 week low of 2.31 set on Oct 30, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.50 |
---|---|
High | 6.50 |
Low | 5.81 |
Bid | 5.62 |
Offer | 7.84 |
Previous close | 6.41 |
Average volume | 38.53k |
---|---|
Shares outstanding | 5.35m |
Free float | 5.19m |
P/E (TTM) | -- |
Market cap | 34.28m USD |
EPS (TTM) | -1.71 USD |
Data delayed at least 15 minutes, as of Jul 24 2024 21:00 BST.
More ▼